• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Taiwan·Healthcare·4747.TWO
Share

Johnson Chemical Pharmaceutical Works Co., Ltd. Stocks

NT$ 49.8Last Updated 24.07.2026

Issuer Rating

3/7
Performance

Average

Risk

Considerable

Recommendation

Sell

Market Cap

NT$ 67.43M

NT$ 49.8
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Johnson Chemical Pharmaceutical Works Co., Ltd., established in 1959 and headquartered in New Taipei City, Taiwan, is a Taiwanese company that engages in the manufacturing, importing, and distribution of pharmaceutical raw materials, active ingredients, and finished drug products. The company's diverse product portfolio addresses a wide spectrum of health conditions, encompassing areas such as the central nervous system, respiratory, cardiovascular, gastrointestinal, and endocrine systems, alongside offerings for vitamin supplementation, anti-inflammatory needs, cough and cold remedies, and pain relief. These medicinal products are available in various forms, including traditional solid oral dosages like capsules, tablets, powders, and granules, as well as specialized delivery systems such as nasal sprays.

Company Valuation

Overvalued
2/7

Based on key historical and expected multiples, the stock is overvalued relative to its peers. Specifically, the stock is fairly valued on P/E, overvalued on EV/EBITD.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

26.07.2026 21:33

Revolut Valued at $115 Billion and a Record-Breaking Deal in Asia: Key Takeaways on IPOs as of July 26

26.07.2026 15:01

AI Tools to Combat Cognitive Biases: How Investors Can Use Them

25.07.2026 16:01

Small caps last week: New Nasdaq rules, AI hurting Tripadvisor, Archer's rotorcraft

25.07.2026 13:50

Chevron Discussed with the U.S. How to Protect Its Interests in Kazakhstan from the Effects of the War — WSJ

25.07.2026 13:01

The "Three Seas" Risk Zone, Tesla Hit by Expenses, and "Odyssey" — the Driving Force Behind Movie Theaters

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026